Welcome to our dedicated page for AC Immune SEC filings (Ticker: ACIU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AC Immune SA (NASDAQ: ACIU) SEC filings page on Stock Titan provides centralized access to the company’s U.S. regulatory disclosures as a foreign private issuer. AC Immune files annual reports on Form 20-F and furnishes current reports on Form 6-K, which together offer insight into its clinical-stage biopharmaceutical operations focused on precision prevention of neurodegenerative diseases.
Through its 6-K submissions, AC Immune furnishes interim condensed consolidated financial statements prepared under IFRS, management’s discussion and analysis of financial condition and results of operations, and press releases covering clinical and corporate developments. Examples include reports on interim Phase 2 data for the anti-alpha-synuclein active immunotherapy ACI-7104.056 in Parkinson’s disease, strategic pipeline refocusing and workforce reductions, and quarterly cash position and loss figures.
Investors can use these filings to track how AC Immune funds and prioritizes its programs, including active immunotherapies such as ACI-24.060 and ACI-35.030, small-molecule candidates like the NLRP3 inhibitor ACI-19764, and diagnostic PET tracers such as ACI-19626 and ACI-15916. Governance-related filings, including annual general meeting results, board and committee elections, compensation approvals and auditor reappointments, are also furnished on Form 6-K and incorporated by reference into the company’s shelf registration statements.
On Stock Titan, these SEC documents are updated as they are filed with EDGAR, and AI-powered tools can help summarize lengthy 20-F and 6-K materials, highlight key risk factors, and surface important changes in clinical, financial or governance disclosures. This allows users to quickly understand how AC Immune’s regulatory reporting reflects the evolution of its neurodegeneration-focused pipeline and collaboration agreements.